Identifier |
20230313_nanos_stateoftheart1_04 |
Title |
American Perspective - It Could Be MOG |
Creator |
Eric Eggenberger, DO, MSEpi |
Affiliation |
Mayo Clinic Florida, Jacksonville, FL |
Subject |
MOG (Myelin Oligodendrocyte Glycoprotein); MOGAD (MOG Associated Disease); Optic Neuritis; Transverse Myelitis; ADEM (Acute Disseminated Encephalomyelitis) |
Description |
Myelin oligodendrocyte glycoprotein associated disease (MOGAD) is a recently defined distinct syndrome that often manifests as optic neuritis, longitudinally extensive myelitis, acute disseminated encephalomyelitis (ADEM, especially in children) or cortical encephalitis. The term neuromyelitis optica (NMO) has been applied to the clinical phenotype of longitudinally extensive optic neuritis without or without longitudinally extensive transverse myelitis (which may occur in both aquaporin-4 (AQP4) and MOG positivity), while NMO spectrum disease (NMOSD) encompasses a wider spectrum of features, often occurring in the presence of the aquaporin-4 antibody; we will adhere to a antibody-based nomenclature to avoid confusion. |
Date |
2023-03 |
References |
1. Chen JJ, Flanagan EP, Jitprapaikulsan J et al. Myelin associated glycoprotein antibody-positive optic neuritis: clinical characteristics, radiological clues and outcomes. Am J Ophthalmol 2018;195:8- 15.Hasan MB, Stern C, 2. Chen JJ, Tobin WO, Majed M et al. Prevalence of myelin oligodendrocyte glycoprotein and aquaporin-4-IgG in patients in the Optic Neuritis Treatment Trial. JAMA Ophthalmol 2018 Apr 1;136(4):419-422. 3. Chen JJ, Huda S, Hacohen Y et al. Association of maintenance intravenous immunoglobulin with prevention of relapse in adult myelin oligodendrocyte glycoprotein antibody-associated disease. JAMA Neurol 2022. 4. Cobo-Calvo A, Ruiz A, Rollot F et al. Clinical features and risk of relapse in children and adults with myelin oligodendrocyte glycoprotein antibody-associated disease. Ann Neurol 2021;89:30-41 5. Flanagan EP et al. Population based incidence of optic neuritis in the era of aquaporin-4 and myelin oligodendrocyte glycoprotein antibodies. Am J Ophthalmol 2020;220:110-114. 6. Kaneko K, Sato DK, Nakashima I et al. CSF cytokine profile in MOG-IgG+ neurological disease is similar to AQP4-IgG+ NMOSD but distinct form MS. J Neurol Neurosurgery Psychiatry 2018;89:927- 936. 7. Sechi E, Cacciaguerra L, Chen JJ et al. Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): a review of clinical and MRI features, diagnosis and management. Frontiers in Neuro 2022; 13. 8. Sechi E, Buciuc M, Pittock SJ et al. Positive predictive value of myelin oligodendrocyte glycoprotein autoantibody testing. JAMA Neurol 2021;78:741-746. |
Language |
eng |
Format |
application/pdf |
Type |
Text |
Source |
2023 North American Neuro-Ophthalmology Society Annual Meeting |
Relation is Part of |
NANOS Annual Meeting 2023: State of the Art - Global Perspectives |
Collection |
Neuro-ophthalmology Virtual Education Library: NOVEL http://NOVEL.utah.edu |
Publisher |
Spencer S. Eccles Health Sciences Library, University of Utah |
Holding Institution |
North American Neuro-Ophthalmology Association. NANOS Executive Office 5841 Cedar Lake Road, Suite 204, Minneapolis, MN 55416 |
Rights Management |
Copyright 2023. For further information regarding the rights to this collection, please visit: https://NOVEL.utah.edu/about/copyright |
ARK |
ark:/87278/s6jddhcj |
Context URL |
The NANOS Annual Meeting Neuro-Ophthalmology Collection: https://novel.utah.edu/collection/NAM/toc/ |
Setname |
ehsl_novel_nam |
ID |
2309954 |
Reference URL |
https://collections.lib.utah.edu/ark:/87278/s6jddhcj |